Design and development of a soft corticosteroid, loteprednol etabonate

Nicholas Bodor, Peter Buchwald

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

A number of allergic diseases, including asthma and rhinitis, are reaching epidemic proportions within industrialized countries (1). In most of these countries, almost half of the population demonstrates sensitization to one or more environmental allergens, and in some of them, 25% of children under 14 years of age have asthma and 20% have eczema (1). It is becoming clear that these rising trends are due both to increased exposure to sensitizing allergens and to reduced stimulation of the immune system during critical periods of development (1). Even if most allergic diseases are not life threatening, they can cause considerable discomfort for the individual and a considerable total cost of treatment for the society. For example, in the United States in the early 1990s, asthma had a prevalence of around 4% and caused an estimated total yearly cost of $6.2 billion ($3.6 billion direct medical cost and $2.6 billion indirect cost; cost per patient per year being around $640) (2).

Original languageEnglish (US)
Title of host publicationInhaled Steroids in Asthma
Subtitle of host publicationOptimizing Effects in the Airways
PublisherCRC Press
Pages541-564
Number of pages24
ISBN (Electronic)9780203908532
ISBN (Print)9780824705855
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'Design and development of a soft corticosteroid, loteprednol etabonate'. Together they form a unique fingerprint.

Cite this